硫糖铝与抑酸剂联用与单用比较的Meta分析

目的系统评价硫糖铝与抑酸剂联用的有效性和安全性。方法计算机检索Cochrane图书馆临床对照试验资料库(2011年第4期)、MEDLINE、EMbase、中国生物医学文献数据库和中国期刊全文数据库(从建库至2011年11月)。由两位研究者按纳入与排除标准选择随机对照研究评价质量及提取资料后,采用RevMan 4.2软件对数据进行Meta分析。结果初检出11篇文献,经筛选最终纳入7篇文献共7个随机对照研究,包括595例患者。Meta分析结果显示,硫糖铝与抑酸剂联用与单药相比,临床症状有效率OR 1.6,95%CI(0.87,2.93),P=0.13]、胃镜治愈率OR 1.36,95%CI(0.87,2.12),P=0.17]、不良反应发生率OR 1.36,95%CI(0.64,2.90),P=0.42],均无统计学差异。结论现有研究结果表明,硫糖铝与抑酸剂联用与单药相比,未能显著增加疗效和减少不良反应,不优于两者单用。

Meta-analysis: Effect of Monotherapy and Combination Therapy with Sucralfate and Acid Secretion Inhibitor

OBJECTIVE To evaluate the efficacy and safety of combined sucralfate and acid secretion inhibitor.METHODS The Cochrane Central Register of Controlled Trials（Issue 4,2011）,MEDLINE,EMbase,CBM and CNKI（from their inception to November 2011） were searched for relevant studies.Two reviewers independently retrieved randomized controlled trials（RCTs） according to the inclusion and exclusion criteria,assessed the methodological quality of included trials,and extracted data.Meta-analysis was performed by RevMan 4.2 soft.RESULTS Seven RCTs involving 595 patients were ultimately identified.The results of meta-analyses showed combination therapy was not superior to monotherapy in symptom improvement OR 1.6,95%CI（0.87,2.93）,P=0.13],endoscopic healing OR 1.36,95%CI（0.87,2.12）,P=0.17] and adverse events OR 1.36,95%CI（0.64,2.90）,P=0.42].CONCLUSION Combination therapy with sucralfate and acid secretion inhibitor provides no superior in efficacy and safety than monotherapy.